September 22, 2026
Dialybrid Raises €15M in Series A Funding
Dialybrid, a Cantù, Italy-based provider of a vascular access solution for hemodialysis, raised €15M in Series A funding. The round was led by XGEN Venture, with participation from CDP Venture Capital. The company intends to use the funds to advance the clinical development of its Silkothane Arteriovenous Graft as a hemodialysis vascular access, and for […]
Dialybrid, a Cantù, Italy-based provider of a vascular access solution for hemodialysis, raised €15M in Series A funding.
The round was led by XGEN Venture, with participation from CDP Venture Capital.
The company intends to use the funds to advance the clinical development of its Silkothane Arteriovenous Graft as a hemodialysis vascular access, and for preclinical development of the Silkothane® material in other vascular applications.
Led by CEO Francesco Giovanni Greco, Dialybrid is a clinical-stage medical device company developing novel arteriovenous vascular grafts based on Silkothane, a patented hybrid material consisting of silk fibroin and polyurethane. Their platform integrates silk fibroin and polyurethane via electrospinning to deliver a partially resorbable vascular access solution that supports endogenous tissue remodeling while providing mechanical durability.
Don’t just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week—in our structured Master Database (XML) + Weekly Intelligence PDF. 👉 [Access FinSMEs Intelligence Hub]…Read more by FinSMEs